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1. Introduction 
Physicians every day try to accomplish their mission: to give the better care and assistance 
to their individual patients. They know perfectly that an individual subject is typically 
“unique”. He or she has specific characteristics, qualities and features, different perceptions 
of risk value, different values scale, different familiar environments and social roles, all 
together interacting in a complex way. In other words no subject is equivalent to another, 
nor even mono-ovular twins. 
But physician has to take decisions continuously, in front to every single individual, facing 
always with uncertainty. Will my diagnosis be confirmed later on? Will my treatment work 
in this patient? Will this patient follow my indications? These are questions that most 
physicians ask themselves every day. 
Physicians know that an individual patient is not the average representative of the 
population. Rather he or she is a person with unique characteristics. What they not always 
know is that an intervention may be effective for a population but not necessarily for the 
individual patient. The recommendation of a guideline may not be right for a particular 
patient because it is not what he or she wants, and implementing the recommendation will 
not necessarily mean a favourable outcome. 
The fundamental resource for them still remain their experience and their intelligence in 
using experience as a guide. In addition,  increasing expectations of the highest quality of 
health care and the rapid growth of ever more detailed medical knowledge leave the 
physician without adequate time to devote to each patient – who all-too-often becomes a 
case or a file rather than being a person. So, for lack of time, most medical decisions must be 
based on rapid judgments of the "case" relying on the physician's unaided memory. Only in 
rare situations can a literature search or other extended investigations be undertaken to 
assure the doctor (and the patient) that the latest knowledge is being brought to bear on any 
particular malady. Continued training and recertification procedures encourage the 
physician to keep more of the relevant information constantly in mind, but fundamental 
limitations of human memory and recall coupled with the growth of available and 
accessible  knowledge assures that most of what is known cannot be known by most 
individuals. 
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The spectacular development  of information technology and molecular biology has 
increased exponentially the quantity of the information available for the busy physician. It  
is not unusual to  have at hand, especially  when faced with treatment planning for a chronic 
degenerative disorder, hundreds of different variables, consisting of clinical history data, 
objective findings, symptoms, multi-item  scales of different meanings, laboratory 
examinations, etc. With the increased availability and use of functional genomics and digital 
imaging  we now tentatively have at our disposition thousands of data per subject. 
This creates a paradox: in comparison with 10-20 years ago we are now able to collect more 
data per subject than  subjects per study. 
2.The emergence of complexity in medicine 
Non linearity, complexity, fuzzy interaction are emerging features of chronic degenerative 
diseases which account for most morbidity and mortality in western world. Unfortunately 
even the most powerful and well established statistical methods were developed in the first 
half of the past century when the scenario was dominated by acute infective diseases and 
the available information was much more simple, or at maximum “complicated” rather than 
“complex”. comparison with today. 
More features imply more information and potentially higher accuracy. Unfortunately more 
features we have, the more difficult information extraction is. In this high dimensional 
space, the hyper points corresponding to single individuals are sparse and the notion of 
proximity fails to retain its meaningfulness. For this reason clustering become extremely 
hard to be performed. In this situation we are dealing with flat, rectangular data set, a sort of 
telescope data set. This kind of data set are intractable from a traditional statistics point of 
view due to the fact that the excessive amount of degrees of freedom allows any kind of data 
interpolation most of the time meaningless. 
A part from quantitative features, non linearity, complexity, fuzzy interaction are new 
emerging qualitative features of chronic degenerative diseases which account for most 
morbidity and mortality in western world. Unfortunately even the most powerful and well 
established statistical methods were developed in the first half of the past century when the 
scenario was dominated  by acute infective diseases and the available information was 
much more simple, or at maximum “complicated” rather than “complex”.  comparison with 
today. 
There is now the reason to ask a fundamental question: is the mathematics used in medicine 
what it should be given the complexity of the chronic degenerative diseases?  
There are a number of different reasons to apply complex systems mathematics on 
predictive medicine and some of them are listed in the table 1.  
 
Processes are based on complex networks of interacting genes and proteins.  
Health status is the consequence of dynamic processes that regulate these networks 
Non linear critical thresholds link to  pathology  
The predictions have to be applied   at individual patient level. 
Huge amount of data per subject hamper statistical tests 
Table 1. Motivations to apply complex systems mathematics on predictive medicine 
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Complexity is based on small elementary units working together in small populations of 
synchronous processes. In a complex system each component changes, over time, losing its 
identity outside of the system. Complexity needs a different kind of mathematics, able to 
handle chaotic behaviour, non linear dynamics, and fractal geometry (Kaplan & Glass,1995; 
Goldberger, 1996). 
Computational and mathematical medicine needs different statistical approaches, based on 
new mathematical and logic assumptions broadly belonging to complex theory setting allow 
to tame these intractable data sets. Seen in this perspective computer science is now playing 
the role which mathematics did from the seventeenth through the twentieth centuries: 
providing an orderly, formal framework and exploratory apparatus for knowledge 
progress. 
Actually the coupling of computer science and these new theoretical bases coming from 
complex systems mathematics allows the creation of “intelligent” agents able to adapt 
themselves dynamically to problem of high complexity: the Artificial Neural Networks 
(ANNs).  
3. Artificial Neural Networks 
Artificial Neural Networks  are adaptive models for the analysis of data which are inspired 
by the functioning processes of the human brain. They are systems which are able to modify 
their internal structure in relation to a function objective and  are particularly suited for 
solving problems of the non linear type, being able to reconstruct the approximate rules that 
put a certain set of data - which describing the underlying problem with a particular target ( 
specific diagnosis, outcome etc.). 
They are particularly suited for solving problems of the non linear type, being able to 
reconstruct the approximate rules that put a certain set of data - which describes the 
problem being considered - with a set of data which provides the solution. For a detailed 
description of these models and tools we refer to recent reviews (Grossi & Buscema, 2007; 
Grossi & Buscema, 2006)  
The base elements of the ANNs are the nodes, also called processing elements, and the 
connections. Each node has its own input, from which it receives communications from 
other nodes and/or from the environment and its own output, from which it communicates 
with other nodes or with the environment. Finally, each node has a function f through 
which it transforms its own global input into output (see figure 1). 
Each connection is characterized by the strength with which pairs of nodes are excited or 
inhibited. Positive values indicate excitatory connections, the negative ones inhibitory 
connections. 
The connections between the nodes can modify themselves over time. This dynamic starts a 
learning process in the entire ANNs. The way through which the nodes modify themselves 
is called “Law of Learning”. The total dynamic of an ANNs is tied to time. In fact, for the 
ANNs to modify its own connections, the environment has to necessarily act on the ANNs 
more times. Data are the environment which acts on the ANNs. 
The learning process is, therefore, one of the key mechanisms that characterize the ANNs, 
which are considered adaptive processing systems. The learning process is one way to adapt 
the connections of an ANNs to the data structure that make up the environment and, 
therefore, a way to “understand” the environment and the relations that characterize it. 
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Fig. 1. Example of Supervised artificial neural network. The architecture is that of back 
propagation neural network with one layer of input nodes, corresponding to independent  
variables, two layers of hidden nodes allowing the integration of non linear functions, and 
one layer of output nodes corresponding to the target variables. 
The raw indicate the direction of flow of data along the network. 
4. Evolutionary algorithms 
At variance with neural networks which are adaptive systems able to discover the optimal 
hidden rules explaining a certain data set, Evolutionary Algorithms (EA) are Artificial 
Adaptive Systems able to find optimal data  when fixed rules or constraints have to be 
respected. They are in other words optimisation tools which become fundamental when the 
space of possible states in a dynamic system tends toward infinitum. 
An EA for example can help to distribute the original sample in two or more sub-samples 
with the aim of obtaining the maximum performance possible from an ANN that is trained 
on the first sample and tested on the second. It is possible, in order to limit eventual 
optimistic polarizations in the evaluation of the performance, to invert the two samples and 
to consider the mean between the two approximations obtained as fitness of the algorithm 
and as an estimate of the model’s quality. 
Also the problem to select among the different variables available those most related to a 
particular outcome without the recur to linear correlation parameters can be approached 
with EA. When linear systems are used, an instrument exists, correlation index , which 
indicates the degree of relationship existing between the input and output variables of the 
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system, in this way suggesting which of the variables available to use to build a model of the 
problem. The problem of selecting a subset of variables on which to build the model for the 
process under examination stems from the fact that, when data are gathered to build the 
Data Base, the relationship between the  collected variables and the function of the process 
being examined is not known. In this case the natural approach is to include  all of the 
variables that may have a connection with the event being studied. The result of this 
approach is that often a series of variables which do not contain any information regarding 
the process being examined are present. These variables, inserted in the model, cause an 
increase of the noise and therefore a greater difficulty for the ANN to learn the data 
correctly. 
The coupling of ANN and EA and brings to the concept of artificial organisms, able to 
optimize the classification performance and prediction ability. 
Training & Testing and Input Selection  which have been combine in a single system called 
TWIST (Buscema, 2007-2008) are example of such artificial organisms which are devoted to 
the problems above discussed respectively. 
5. Basic philosophy of Artificial Neural Networks 
The basic principle which is proposed in ANNs is very simple:  all the biological signals 
from all the sources available are analyzed together -and not individually- both in time and 
space. The reason for such an approach is quite simple and self-explaining: the instant value 
of the system in any recording source depends, in fact, upon its previous and following 
values (how many, and in which amount for each previous state?), upon the previous and 
following values of all the other recording sources (how many, and in which amount for 
each previous state?). 
In summary, the aim of the “analyzer” is not to analyze the language of each individual 
variable, but to evaluate the meta-language which considers the holistic contribution of all 
the recorded variables. We, in fact, believe that the equilibrium of each individual subject is 
defined by a specific background signal model, distributed in time and in the space. Such a 
model is a set of background invariant features able to specify the quality of the immune 
activity for example. The system that we propose to apply in this research context 
completely ignores the subject’s contingent characteristics. It utilizes a recurrent procedure 
which squeezes at progressive steps the significant signal and progressively eliminates the 
non-significant noise.  
6. The paradigm shifts of Artificial Neural Networks in predictive medicine 
The use of ANNs and in particular  Neural Networks are already emerging   as new trends 
in medical statistics. Although  these methods are not yet  in widespread use, they have 
already had a clinical impact in specific areas, notably cervical cytology, x-Ray 
mammography and early detection of acute myocardial infarction where large-scale 
prospective multicenter studies have been carried out. Extensive reviews on this subject has 
been published (Lisboa, 2002).  
There are in the literature many examples of successful application of ANN in outcome 
research. 
Our group has proved the usefulness of the added predictive value gained with the use of 
advanced artificial neural networks coupled in a number of medical fields, ranging from 
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heart diseases, gastroenterology and neurology with special regard to Alzheimer disease, 
stroke and Amyotrophic Lateral Sclerosis. 
Our group has proved the usefulness of the added predictive value gained with the use of 
advanced artificial neural networks coupled with evolutionary algorithms in a number of 
medical fields, ranging from heart diseases, gastroenterology and neurology with special 
regard to Alzheimer disease, stroke and Amyotrophic Lateral Sclerosis (Street et al., 2008; 
Grossi, 2006). 
ANNs bring a number of revolutionary paradigm shifts which will have a strong impact in 
predictive medicine. They are listed in the table 2. 
 
No limitation in the amount of  data processed 
No limitation in the different nature of data processed 
No limitation in the degree of complexity of data processed 
Bottom - up computation: models are data driven 
Interactions among different factors are easily picked-up 
Inference takes place at individual level 
Internal validity of modelling ensured with validation protocols 
Fuzzy logic allows to escape  from the probability theory trap 
Table 2. Paradigm shift introduced by ANNs in medicine 
ANNs are able to reproduce the dynamical interaction of multiple factors simultaneously, 
allowing the study of complexity; this is very important for the researcher interested to deep 
the knowledge of a specific disease or to better understand the possible implications relative 
to strange associations among variables. This has to do to what is called “intelligent data 
mining”. But one the other hand ANNs can also help medical doctors in making decisions 
under extreme uncertainty and to draw conclusions on individual basis and not as average 
trends. The modern patient wants to be treated as an individual person and not just as a 
statistics. Patients want to know their own risk, not just a parameter regarding a class of 
people similar to them just for some aspects. ANNs are very powerful in modelling at single 
individual level, and by combining several parallel ANNs trained on the same data set is 
possible to make multiple statistics on a single subject, allowing in this way the calculation 
of the confidence interval of the prediction estimate. Finally ANNs make possible to treat 
huge amount of information without squeezing arbitrarily the data and without  loosing 
complexity. This  contributes to a new holistic vision of the human subject contrasting the 
statistical reductionism, which tends to squeeze or even delete the single subject sacrificing 
him to his group of belongingness. A remarkable contribution to this individual approach 
comes from Fuzzy Logic, according to which there are no sharp limits between opposite 
things, like health and disease. This approach allows to partially escape from probability 
theory trap in situations where is fundamental to express a judgment based on a single case 
and favours a novel humanism directed to the management of the patient as individual 
subject. 
7. The unfulfilled dream: prediction of individual response to treatments 
Making predictions for specific outcomes (diagnosis, risk assessment, prognosis) represents 
a fascinating aspect of medical science. Different statistical approaches have been proposed 
to define models to identify factors that are predictive for the outcome of interest. Studies 
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have been performed to define the clinical and biological characteristics that could be 
helpful in predicting who will benefit from an anti-obesity drug for example, but results 
have been limited (Padwal et al., 2003). 
Traditional statistical approaches encounter problems when the data show big variability  
and not easily normalized for inherent nonlinearity. More-advanced analysis techniques, 
such as dynamic mathematical models, can be useful because they are particularly suitable 
for solving nonlinear problems frequently associated with complex biological systems. 
Use of ANNs in biological systems has been proposed for different purposes, including 
studies on deoxyribonucleic acid sequencing (Parbhane et al., 2000) and protein structure 
(Jagla & Schuchhardt, 2000). 
ANNs have been used in different clinical settings to predict the effectiveness of 
instrumental evaluation (echocardiography, brain single photon emission computed 
tomography, lung scans, prostate biopsy) in increasing diagnostic sensitivity and specificity 
and in laboratory medicine in general (Tafeit & Reibnegger, 1999). Also, they have proven 
effective in identifying gastro-oesophageal refux patients on the sole basis of clinical data 
(Pace et al., 2005). But the most promising application of ANNs relates to prediction of 
possible clinical outcomes with specific therapy. ANNs have proven effective in detecting 
responsiveness to methadone treatments of drug addicts (Massini & Shabtay, 1998), to 
pharmacological treatment in Alzheimer disease (Mecocci et al., 2002), to clozapine in 
schizophrenic patients (Lin et al., 2008) and in various fields of psychiatric research (Politi et 
al., 1999).  
The use of ANNs for predictive modelling in obesity dates back to a decade ago, where it 
was proposed to model the waist-hip ratio from 13 other health parameters (Abdel-Aal & 
Mangoud, 1997). Later, it has been proposed as a tool for body composition research (Linder 
et al., 2003).  
One of the main factors preventing a more efficient use of new pharmacological treatments  
for chronic diseases like for example hypertension, cancer, Alzheimer disease or obesity is 
represented by the difficulty of predicting “a priori” the chance of response of the single 
patient to a specific drug.  A major methodological setback in drawing inferences and 
making predictions from data collected in the real world setting, such as observational 
studies, is that variability in the underlying biological substrates of the studied population 
and the quality and content of medical intervention influence outcomes. Because there is no 
reason to believe that these, like other health factors, work together in a linear manner, the 
traditional statistical methods, based on the generalized linear model, have limited value in 
predicting outcomes such as responsiveness to a particular drug.  
Most studies have shown that up to 50% of patients treated with new molecules given in 
monotherapy or as an adjunct to standard  treatments may show an unsatisfactory response. 
As a matter of fact, when time comes for the physician to decide about type of treatment, 
there is very little evidence that can help her/him in drug treatment choice. Take for 
example obesity. Here only scanty data are available on predictive factors to the specific 
treatment, and attempts at developing models for predicting response to the drug by using 
traditional techniques of multiple regression have showed an unsatisfactory predictive 
capacity (i.e. inferior to 80% of total variance). (Hansen et al., 2001; Hainer et al., 2005). A 
possible explanation could be that obesity is a so-called complex disease, where different 
factors interact with multiple interactions among variables, positive and negative feedback 
loops, and non-linear system dynamics. Another good example is Alzheimer Disease. 
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Clinical trials have established the efficacy of cholinesterase inhibitor drugs (ChEI), such as 
tacrine, (Knopman et al., 1996) donepezil, (Rogers et al., 1998) and rivastigmine (Rösler et al., 
1999) based on improvement in cognitive aspects and in overall functioning using the 
Alzheimer’s Disease Scale—Cognitive subscale (ADAS-Cog) and the Clinician’s Interviewed 
Based Impression of Change (CIBIC), respectively. Although the mean score of treated 
patients in both scales was significantly higher than the placebo group, many subjects under 
active treatment showed little or no improvement (non-responders). 
However it is not possible to estimate which patients are likely to respond to 
pharmacological therapy with ChEI. This prediction would be an important decision-
making factor in improving the use of healthcare resources. 
A major methodological setback in drawing inferences and making predictions from data 
collected in the real world setting, such as observational studies, is that variability in the 
underlying biological substrates of the studied population and the quality and content of 
medical intervention influence outcomes.  
Because there is no reason, a priori, to believe that these, like other health factors, work 
together in a linear manner, the traditional statistical methods, based on the generalized 
linear model, have limited value in predicting outcomes such as responsiveness to a 
particular drug. 
A possible alternative approach to the solution of the problem is represented by the use of 
Neural Networks. 
Although ANNs have been applied to various areas of medical research, they have not been 
employed intensively clinical pharmacology as they might deserve. 
In our personal experience ANNs proved to be a useful method to discriminate between 
responders and non-responders, better than traditional statistical methods in our three 
experimental studies carried out with donepezil in Alzheimer disease and with sibutramine 
in obesity and with infliximab in Crohn disease. 
In a paper published in 2002 (Mecocci, 2002) we have evaluated the accuracy of artificial 
neural networks compared with discriminant analysis in classifying positive and negative 
response to the cholinesterase inhibitor donepezil in a opportunistic  group of  61 old 
patients of both genders affected by Alzheimer’s disease (AD) patients in real world setting 
along three months follow-up. 
Accuracy in detecting subjects sensitive (responders) or not (non responders) to therapy was 
based on  the standard FDA criterion standard for evaluation of efficacy:  the scores of 
Alzheimer’s Disease Assessment Scale—Cognitive portion and Clinician’s Interview Based 
Impression of Change—plus scales. In this study ANNs were more effective in 
discriminating between responders and nonresponders than other advanced statistical 
methods, particularly linear discriminant analysis. The total accuracy in predicting the 
outcome was 92.59%. 
In a second study we evaluated the performance of ANN in predicting response to 
Sibutramine treatment in obese patients (Petroni et al., in press). Out of 162 patients treated 
in an open-label multicentre study with 6-month Sibutramine 10 mg/day, increased to 15 
mg/day if weight loss ≤ 5% after 3 months, we evaluated 92 obese subjects (10 M, 82 F, 
mean age 44.2 ± 12.4) with full data set available. Patients were considered responders if 
body weight loss was ≥ 5% at the end of the study. At descriptive analysis, non-responders 
(n=26) only differed from responders (n=66) in having significantly lower values of TSH and 
in having a more frequent history of previous dietary or pharmacological treatment for 
weight loss. Out of 84 baseline variables, after a preliminary analysis, 33 variables which 
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best discriminated between responders and non-responders were selected; a logistic 
regression (LR) was also performed on same variables. The overall mean accuracy of ANN 
detection of responders was 79.1%, being correctly recognised in 90.5%; predictive model 
could not be developed by LR . Among baseline predictive variables, those with the highest 
“input relevance” were: previous drug treatment, android fat distribution, alcohol 
consumption, HDL cholesterol, hypertension; variables that also significantly contributed to 
the model were: previous dietary treatment, pregnancies, abnormal lipid profile, physical 
activity, FT4, heart rate, diastolic blood pressure, obesity in siblings, previous smoking, 
triglycerides, age, basal energy expenditure, weight at 20 years, current smoking, TSH, 
creatinine. In Conclusion ANN proved to be a useful method to discriminate between 
responders and non-responders, better than traditional statistical methods.  
Finally in a third study we evaluated the use of artificial neural networks  in predicting 
response to infliximab treatment in patients with Crohn's disease(Kohn et al., 2005). 
In this pilot study , different ANN models were applied to a data sheet with demographic 
and clinical data  from 76 patients with steroid resistant/dependant or fistulizing  CD 
treated with Infliximab to compare accuracy in classifying responder and non responder 
subjects with that of linear discriminant analysis. 
Eighty one  outpatients  with CD (31 men, 50 women;  mean age± standard deviation  39.9 ± 
15  range: 12-81 ) participating to an Italian Multicentric Study (Parbhane et al., 2000), were 
enrolled in the study. All patients  were treated, between April 1999 and December 2003, 
with a dose of Infliximab 5 mg/kg of body weight  for  luminal refractory (CDAI > 220–400) 
(43 patients), fistulizing  CD (19 patients) or both of them (14 patients). 
The final data  sheet consisted of 45 independent variables related to the anagraphic and 
anamnestic data (sex, age at diagnosis, age at infusion, smoking habit, previous Crohn’s 
related abdominal surgery [ileal or ileo-cecal resections] and concomitant treatments 
including immunomodulators and corticosteroids) and to clinical aspects (location of 
disease, perianal disease, type of fistulas,  extraintestinal manifestations, clinical activity at 
the first infusion  [CDAI], indication for treatment). Smokers were defined as those smoking 
a minimum of 5 cigarettes per day for at least 6 months before their first dose of Infliximab.  
Non smokers were defined as those who had never smoked before, those who had quit 
smoking at least 6 months before their first dose of Infliximab, or those who smoked fewer 
than 5 cigarettes per day. Concomitant immunosuppressive use was defined as initiation of 
methotrexate  before their first Infliximab infusion or initiation of 6-mercaptopurine (6-MP) 
or azathioprine more than 3 months before their first Infliximab infusion. 
Assessment of response was determined by clinical evaluation 12 weeks after the first 
infusion for all patients. Determination of response in patients with inflammatory CD was 
based on the Crohn’s Disease Activity Index (CDAI).  For clear - cut estimate clinical 
response was evaluated as complete response or partial / no response.   
Complete response was defined as (a) clinical remission (CDAI < 150) in luminal refractory  
disease and (b) temporary closure of all draining fistulas at consecutive visits in the case of 
enterocutaneous and perianal fistulas; entero-enteric  fistulas  were evaluated by  small 
bowel barium enema and vaginal-bladder fistula  by lack  of drainage at consecutive visits. 
For patients with both indications the outcome was evaluated independently for each 
indication. 
Two different experiments were planned following an identical  research protocol. The first 
one included all 45 independent variables including frequency and intensity Crohn disease 
symptoms, plus numerous other social and demographic characteristics, clinical features 
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and history. In the second experiment the IS system coupled to the T&T system 
automatically selected the most relevant variables and therefore 22 variables were included 
in the model. 
Discriminant analysis was also performed on the same data sets to evaluate the predictive 
performance of this advanced statistical method by a statistician blinded to ANN results. 
Different models were assessed to optimise the predictive ability. In each experiment the 
sample was randomly divided into two sub-samples, one for the training phase and the 
other for the testing phase, with the same record distributions used for ANN validation. 
ANNs reached an overall accuracy rate of 88% while LDA performance was only of 72%. 
8. Conclusions 
New mathematical laws coupled by computer programming allow today to perform 
predictions which till few years ago were considered impossible. The prediction of response 
to a specific treatment in individual patients with supervised artificial neural networks has 
been documented and validated extensively in the literature. Less experience exists in 
predicting major unwanted effects of a new drugs after the commercialisation. In doing this 
task a close cooperation between regulatory agency scientific team and bio mathematicians 
experts in the use of new generations artificial adaptive system has to be strongly 
recommended. 
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